MediGene Announces Change to Supervisory Board

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

Martinsried/Munich, October 31, 2008. MediGene AG (Frankfurt, Prime
Standard: MDG) announces that Dr. Thomas Strüngmann, Managing
Director of Santo Holding (Germany) GmbH, will resign from his role
as a Supervisory Board member of MediGene AG for personal reasons,
effective from January 1, 2009.

Prof. Dr. Ernst-Ludwig Winnacker, Chairman of MediGene's Supervisory
Board commented: "We very much regret the fact that Dr. Strüngmann
has resigned from office. He showed great commitment on our
Supervisory Board, and through his expertise he contributed
significantly to the refocusing of our company's strategy. On behalf
of both our Supervisory and Executive Boards, I would like to express
my heartfelt thanks to him."

This press release contains forward-looking statements representing
the opinion of MediGene as of the date of this release. The actual
results achieved by MediGene may differ significantly from the
statements made herein. MediGene is not bound to update any of these
forward-looking statements. MediGene® is a registered trademark of
MediGene AG. This trademark may be owned or licensed in select
locations only.

- ends -

MediGene AG is a publicly listed (Frankfurt, Prime Standard: MDG)
biotechnology company located in Martinsried/Munich, Germany, with
subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first
German biotech company to have drugs on the market, which are being
distributed by partner companies. MediGene has several drug
candidates in clinical development, two of which providing a very
high sales potential. In addition, the company has numerous projects
in research and pre-clinical development and possesses innovative
platform technologies. MediGene focuses on the research and
development of novel drugs for the treatment of cancer and autoimmune
diseases.

Contact MediGene AG
E-mail: investor@medigene.com
Fax: +49 - 89 - 85 65 - 2920
Julia Hofmann / Dr. Nadja Wolf, Public Relations, Tel.: +49 - 89 - 85
65 - 3324
Dr. Georg Dönges, Investor Relations, Tel.: +49 - 89 - 85 65 - 2946

--- End of Message ---

MediGene AG
Lochhamer Strasse 11 Martinsried / München Germany

WKN:
502090; ISIN: DE0005020903 ;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in
Bayerische Börse München,
Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr
in Niedersächsische Börse zu Hannover,
Geregelter Markt in Frankfurter Wertpapierbörse;
Copyright © Hugin AS 2008. All rights reserved.